|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.12/0.83
|
企业价值
3.42B
|
资产负债 |
每股账面净值
12.50
|
现金流量 |
现金流量率
--
|
损益表 |
收益
366.38M
|
每股收益
6.72
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/29 03:04 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets. |